These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 25399731)

  • 1. Angiotensin blockade in late autosomal dominant polycystic kidney disease.
    Torres VE; Abebe KZ; Chapman AB; Schrier RW; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Moore CG; Perrone RD;
    N Engl J Med; 2014 Dec; 371(24):2267-76. PubMed ID: 25399731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blood pressure in early autosomal dominant polycystic kidney disease.
    Schrier RW; Abebe KZ; Perrone RD; Torres VE; Braun WE; Steinman TI; Winklhofer FT; Brosnahan G; Czarnecki PG; Hogan MC; Miskulin DC; Rahbari-Oskoui FF; Grantham JJ; Harris PC; Flessner MF; Bae KT; Moore CG; Chapman AB;
    N Engl J Med; 2014 Dec; 371(24):2255-66. PubMed ID: 25399733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined angiotensin inhibition for the treatment of diabetic nephropathy.
    Fried LF; Emanuele N; Zhang JH; Brophy M; Conner TA; Duckworth W; Leehey DJ; McCullough PA; O'Connor T; Palevsky PM; Reilly RF; Seliger SL; Warren SR; Watnick S; Peduzzi P; Guarino P;
    N Engl J Med; 2013 Nov; 369(20):1892-903. PubMed ID: 24206457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of Progression in Early Autosomal Dominant Polycystic Kidney Disease: Is it Blood Pressure or Renin-Angiotensin-Aldosterone-System Blockade?
    Brosnahan GM; Abebe KZ; Moore CG; Bae KT; Braun WE; Chapman AB; Flessner MF; Harris PC; Hogan MC; Perrone RD; Rahbari-Oskoui FF; Steinman TI; Torres VE; The Halt Pkd Investigators
    Curr Hypertens Rev; 2018; 14(1):39-47. PubMed ID: 29564978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
    Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
    Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of baseline parameters in the HALT polycystic kidney disease trials.
    Torres VE; Chapman AB; Perrone RD; Bae KT; Abebe KZ; Bost JE; Miskulin DC; Steinman TI; Braun WE; Winklhofer FT; Hogan MC; Oskoui FR; Kelleher C; Masoumi A; Glockner J; Halin NJ; Martin DR; Remer E; Patel N; Pedrosa I; Wetzel LH; Thompson PA; Miller JP; Meyers CM; Schrier RW;
    Kidney Int; 2012 Mar; 81(6):577-85. PubMed ID: 22205355
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease.
    Clark LA; Whitmire S; Patton S; Clark C; Blanchette CM; Howden R
    J Med Econ; 2017 Jul; 20(7):715-722. PubMed ID: 28332417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).
    Fried LF; Duckworth W; Zhang JH; O'Connor T; Brophy M; Emanuele N; Huang GD; McCullough PA; Palevsky PM; Seliger S; Warren SR; Peduzzi P;
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):361-8. PubMed ID: 19118120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A quest--halting the progression of autosomal dominant polycystic kidney disease.
    Ellison DH; Ingelfinger JR
    N Engl J Med; 2014 Dec; 371(24):2329-31. PubMed ID: 25399732
    [No Abstract]   [Full Text] [Related]  

  • 11. Beneficial effect of lisinopril plus telmisartan in patients with type 2 diabetes, microalbuminuria and hypertension.
    Sengul AM; Altuntas Y; Kürklü A; Aydin L
    Diabetes Res Clin Pract; 2006 Feb; 71(2):210-9. PubMed ID: 16112244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.
    Clase CM; Barzilay J; Gao P; Smyth A; Schmieder RE; Tobe S; Teo KK; Yusuf S; Mann JF
    Kidney Int; 2017 Mar; 91(3):683-690. PubMed ID: 27927602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HALT polycystic kidney disease trials: design and implementation.
    Chapman AB; Torres VE; Perrone RD; Steinman TI; Bae KT; Miller JP; Miskulin DC; Rahbari Oskoui F; Masoumi A; Hogan MC; Winklhofer FT; Braun W; Thompson PA; Meyers CM; Kelleher C; Schrier RW
    Clin J Am Soc Nephrol; 2010 Jan; 5(1):102-9. PubMed ID: 20089507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J; Barrio V; Goicoechea MA; González C; de Vinuesa SG; Gómez F; Bernis C; Espinosa M; Ahijado F; Gómez J; Escalada P
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
    Torres VE; Higashihara E; Devuyst O; Chapman AB; Gansevoort RT; Grantham JJ; Perrone RD; Ouyang J; Blais JD; Czerwiec FS;
    Clin J Am Soc Nephrol; 2016 May; 11(5):803-811. PubMed ID: 26912543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects of calcium channel blockers and renin-angiotensin-aldosterone system inhibitors on changes in the estimated glomerular filtration rate in patients with polycystic kidney disease.
    Mitobe M; Yoshida T; Sugiura H; Shiohira S; Shimada K; Nitta K; Tsuchiya K
    Clin Exp Nephrol; 2010 Dec; 14(6):573-7. PubMed ID: 20700620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies.
    Chapman AB
    Clin J Am Soc Nephrol; 2008 Jul; 3(4):1197-204. PubMed ID: 18579674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.
    Tobe SW; Clase CM; Gao P; McQueen M; Grosshennig A; Wang X; Teo KK; Yusuf S; Mann JF;
    Circulation; 2011 Mar; 123(10):1098-107. PubMed ID: 21357827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of loss of renal function over time in patients with diabetic nephropathy.
    Barnett A
    Am J Med; 2006 May; 119(5 Suppl 1):S40-7. PubMed ID: 16563947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.